These 10 Firms Crushed The Market Last Week. In this article, we are going to take a look at where Spero Therapeutics, Inc.

In the last week, the market has been flat, but over the past 12 months, it has risen by 12%, with earnings forecast to grow by 14% annually. While traditional investments often focus on established ...

Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock surge by 240% on May 28 following the company’s announcement of the ...

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh ...

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral ...

Major health sector news includes GSK and Spero stopping a UTI drug trial due to early success, Brazil's bird flu cases and ...

Shares of Spero Therapeutics gained after the company and GSK ended their trial for a treatment for complicated urinary tract infections early after it met its primary endpoint. The stock more than ...

Spero Therapeutics (SPRO) stock jumps as GSK (GSK) partnered oral UTI treatment, tebipenem HBr, succeeds in a pivotal Phase 3 ...

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC: London, UK Friday, May 30, 2025, 15:00 Hrs [IST] ...

Spero and GSK halt a UTI drug trial due to early success; Sanofi plans vaccine production in Vietnam; Brazil investigates ...

May 28 (Reuters) - Spero Therapeutics (SPRO.O), opens new tab and partner GSK (GSK.L), opens new tab are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...